Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It means that shareholders are paying for the customers movie tickets
We will waite for Q4 results.... let see how our product been sold in the U.S.
We got approval.... :)
3 years to waiting... I hope pay back is tomorrow
Does anyone knows what time the FDA usually announce "through trading hours or after"?
FDMF can stand again with new management... the company has an assets and need to be organized worked out. BK is a failure and he wasted his life and our lifes for nothing.
he said that he has heart issue. what will happen to FDMF if he passed away
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004237/smops/Positive/human_smop_001334.jsp&mid=WC0b01ac058001d127
On 26 July 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Xerava, intended for the treatment of complicated intra-abdominal infections in adults. The applicant for this medicinal product is Tetraphase Pharmaceuticals Ireland Limited.
Xerava will be available as a 50-mg powder for concentrate for solution for infusion. The active substance of Xerava is eravacycline, a fluorocycline belonging to the tetracycline group of antibiotics (ATC code: J01AA13). Eravacycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, thus preventing the incorporation of amino acid residues into elongating peptide chains.
The benefits with Xerava are its ability to effectively treat complicated intra-abdominal infections. The most common side effects are nausea, vomiting and infusion site phlebitis.
The full indication is:
"Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults (see sections 4.4 and 5.1).
Consideration should be given to official guidance on the appropriate use of antibacterial agents."
Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
2s hopefully soon :)
honestly No... I have been here for many years and never happened what he said...
We need a good news to takeoff...
Years of waiting.....
Looking to the agreement below, a huge cost of manufacturing eravacycline won't be affecting the company cash
On June 14, 2017, Tetraphase Pharmaceuticals, Inc. (the “Company”) and Patheon UK Limited and certain of its affiliates (collectively, “Patheon”) entered into a Master Manufacturing Services Agreement (the “Master Agreement”). Under the Master Agreement, the Company is responsible for supplying the active pharmaceutical ingredient for eravacycline to Patheon, and Patheon is responsible for manufacturing eravacycline, conducting quality control, quality assurance, analytical testing and stability testing and packaging.
Item 2.02 Results of Operations and Financial Condition.
On July 27, 2017, in a preliminary prospectus supplement filed with the SEC, the Company disclosed that its cash and cash equivalents as of June 30, 2017 was approximately $118.2 million
On January 17, 2017, we entered into sales agreement with a sales agent in respect of an“at-the-market” offering program. On July 7, 2017, we entered into an amendment to the sales agreement to increase the maximum aggregate offering price of the shares of our common stock that we may issue and sell from time to time under the sales agreement from $40,000,000 to $80,000,000. As of July 27, 2017, we had sold 3,935,450 shares of our common stock under the sales agreement at an average price of $7.78 per share for an aggregate offering price of $30.6 million, before deducting sales commissions and offering expenses, which includes 611,865 shares sold on July 26, 2017 at an average price of $7.79 per share for an aggregate offering price of approximately $4.76 million, before deducting sales commissions and offering expenses.
the Company expects to receive net proceeds from the offering of approximately $60.9 million (or approximately $70.1 million if the Underwriters exercise in full their option to purchase additional shares of common stock).
Which means they have $118.2M + $35.4M + $60.9M or $70.1M=$214.5M or $223.7M
Yes :(
Missing a PR
We are still waiting for the news ?
We have no option to exist..
"On October 1, 2015, Mr. Brian Kistler resigned as a member of the Board of Directors (“Board”) of Success Holding Group International, Inc. (the “Company”). The resignation is not in connection with any disagreement with the management of the Company and Mr. Kistler will remain as the President of the Company."
Won't run without real news!!!
Great thank you Sir
I don't know what is happening with him!!
I received 2 emails
Hello,
Please find the attached files sent with DROP BOX. Kindly confirmed the receipt of this email.
Brian Kistler
531 Airport North Office Park
Fort Wayne, Indiana 46825
260-490-9990 Office
260-450-3570 Cell
866-745-8713 Fax
bkis2323 - skype
On Sep 22, 2015 3:52 PM, "Brian Kistler" <bkiss2323@aol.com> wrote:
Hello,
Please confirm this documents i sent to you. Let me know if you received it.
--
Brian Kistler
531 Airport North Office Park
Fort Wayne, Indiana 46825
260-490-9980 Office
260-450-3579 Cell
866-745-8714 Fax
bkis2323 Skype